In the BioHarmony Drug Report Database
Polatuzumab vedotin-piiq
Polivy (polatuzumab vedotin) is an antibody pharmaceutical. Polatuzumab vedotin was first approved as Polivy on 2019-06-10. It is used to treat large b-cell lymphoma diffuse in the USA. It has been approved in Europe to treat b-cell lymphoma. The pharmaceutical is active against B-cell antigen receptor complex-associated protein beta chain.
Trade Name
|
Polivy |
|---|---|
Common Name
|
polatuzumab vedotin |
ChEMBL ID
|
CHEMBL3301582 |
Indication
|
b-cell lymphoma, large b-cell lymphoma diffuse |
Drug Class
|
Synthetic analogs of the dolastatin series; monoclonal antibodies: humanized, tumors as target |
Image (chem structure or protein)
